# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $26 to $30.
HROW: 20% | Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale...
Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural...
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑...
Lake Street analyst Brooks O'Neil maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $20 to $25.